Asymptomatic people who have an estimated selleckchem multifactorial CVD risk >20% over 10 years.
People with diabetes mellitus (type 1 or 2). People with elevated blood pressure >160 mmHg systolic or >100 mmHg diastolic, or lesser degrees of blood pressure elevation with target organ damage. People with elevated total cholesterol to high-density lipoprotein cholesterol ratio >6.0. People with familial dyslipidaemia. NICE does not recommend a specific CVD risk calculation for the UK population [186]. Cohort data have demonstrated that the observed myocardial infarction (MI) rates in HIV-seropositive people in developed countries paralleled those predicted by the Framingham risk equation [187] but the extent to which this can be extrapolated to women and men of non-European ethnicity is unknown. Therefore, there is insufficient evidence to recommend a specific CVD risk calculation for the population of HIV-positive adults in UK. The Framingham CVD risk calculator works reasonably well in HIV-positive populations, although it is worth noting that it was not developed for use in non-white find more groups. Other
algorithms may be better suited to these populations. A CVD risk calculator has been developed for use in HIV-positive populations (http://www.chip.dk/TOOLS) [188], although it should be noted that this provides 5-year risk estimates rather than the usual 10-year estimates. Alternatively, the QRISK calculator (http://www.qrisk.org) or the QIntervention tool (http://qintervention.org), which also provides an estimate of the risk of developing type II diabetes, can be used. There are insufficient data to inform whether CVD risk should affect the decision to start ART. The SMART trial provides the only randomized data about the effect of ART on CVD risk, but was not powered for a CVD endpoint. Fewer major CVD events were observed in the viral suppression arm but the difference was not statistically significant [189]. In a post hoc analysis, HIV VL <400 copies/mL was associated with fewer CVD events
suggesting that suppression of viraemia may have been protective; CD4 cell count was not significantly associated with CVD events [190, 191]. Several cohort studies have examined changes in rate of cardiovascular events in HIV-positive populations over time since the heptaminol introduction of ART but no clear protective effect was found [192-195]. In the HIV Outpatients Study cohort, baseline CD4 cell count <350 cells/μL was associated with increased CVD risk, but 350–500 cells/μL and use of ART were not; in a parallel case–control study, cases were more likely to have a current (but not baseline or nadir) CD4 cell count of 350–500 cells/μL [196]. The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study found that untreated patients had a lower incidence of MI than those on ART [197] and risk increased with longer exposure to combination therapy [198].
No related posts.